A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer

Cancer Research

Volumn 65, Issue 22, 2005, Pages 10401-10412

  Burger, Angelika M ^a   Gao, Yuguang ^a   Amemiya, Yutaka ^a   Kahn, Harriette J ^a   Kitching, Richard ^c   Yang, Yili ^d   Sun, Ping ^b   Narod, Steven A ^b   Hanna, Wedad M ^a   Seth, Arun K ^a,c,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d NATIONAL CANCER INSTITUTE   (United States)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DISULFIRAM; ESTROGEN RECEPTOR; NSC 25953; NSC 667089; RING DOMAIN PROTEIN; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CANCER ASSOCIATED GENE 2; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CELL GROWTH; CELL STRAIN 3T3; CELL STRAIN HEK293; CELL STRAIN MCF 7; CHROMOSOME 1Q; CONTROLLED STUDY; CORRELATION COEFFICIENT; CYTOGENETICS; EMBRYO; ENZYME ACTIVITY; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; TISSUE MICROARRAY; UBIQUITINATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, ESTROGEN; TRANSFECTION; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 28544431575     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2103     Document Type: Article

References (32)

1. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002;82:373-428.
2. Joazeiro CA, Weissman AM. RING finger proteins: mediators of ubiquitin ligase activity. Cell 2000;102:549-52.
3. Kosarev P, Mayer KF, Hardtke CS. Evaluation and classification of RING-finger domains encoded by the Arabidopsis genome. Genome Biol 2002;3:RESEARCH0016.
4. Pray TR, Parlati F, Huang J, et al. Cell cycle regulatory E3 ubiquitin ligases as anticancer targets. Drug Resist Updat 2002;5:249-58.
5. Burger AM, Seth AK. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 2004;40:2217-29.
6. Burger AM, Salesiotis A, Panayiotakis A, Li H, Seth A Identification of differentially expressed genes in breast cancer. Int J Oncol 1996;8:395-400.
7. Burger A, Li H, Zhang XK, et al. Breast cancer genome anatomy: correlation of morphological changes in breast carcinomas with expression of the novel gene product Dil2. Oncogene 1998;16:327-33.
8. Burger AM, Beatty B, Seth A. Function and regulation of novel breast cancer associated genes. J Cancer Res Clin Oncol 1999;125:S15-6.
9. Burger AM, Zhang X, Seth A Detection of novel genes that are up-regulated (Di12) or down-regulated (T1A12) with disease progression in breast cancer. Eur J Cancer Prev 1998;7:S29-35.
10. Seth A. Breast cancer associated genes and uses thereof. WO 02/0875707 A2, WIPO;2002.
11. Rennstam K, Ahlstedt-Soini M, Baldetorp B, et al. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res 2003;63:8861-8.
12. Bieche I, Champeme MH, Lidereau R. Loss and gain of distinct regions of chromosome 1q in primary breast cancer. Clin Cancer Res 1995;1:123-7.
13. Mizuno K, Kitamura A, Sasaki T. Rabring7, a novel Rab7 target protein with a RING finger motif. Mol Biol Cell 2003;14:3741-52.
14. Subramaniam V, Lubovitz J, Li H-X Burger A, Kitching R, Seth A. The RING-H2 protein RNF11 is overexpressed in breast cancer and is a target of Smurf2 E3 ligase. Br J Cancer 2003;I89:1538-44.
15. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000;288:874-7.
16. Rice WG, Baker DC, Schaeffer CA, et al. Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob Agents Chemother 1997;41:419-26.
17. Nash T, Rice WG. Efficacies of zinc-finger-active drugs against Giardia lamblia. Antimicrob Agents Chemother 1998;42:1488-92.
18. Shian SG, Kao YR, Wu FY, Wu CW. Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram. Mol Pharmacol 2003;64:1076-84.
19. Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589-601.
20. Landberg G, Ostlund H, Nielsen NH, Emdin S, Burger AM, Seth A. Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpresson, and increased proliferation in estrogen receptor negative tumors. Oncogene 2001;20:3497-505.
21. Rampaul RS, Pinder SE, Elston CW, Ellis IO. Prognostic and predictive factors in primary breast cancer and their role in patient management: the Nottingham Breast Team. Eur J Surg Oncol 2001;27:229-38.
22. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001;10:657-62.
23. Lai Z, Yang T, Kim YB, et al. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 auto-ubiquitination activity by small molecular weight inhibitors. Proc Natl Acad Sci U S A 2002;99:14734-9.
24. Chen A, Kleiman FE, Manley JL, Ouchi T, Pan ZQ. Autoubiquitination of the BRCA1*BARD1 RING ubiquitin ligase. J Biol Chem 2002;277:22085-92.
25. Arihiro K, Oda H, Kaneko M, Inai K. Cytokines facilitate chemotactic motility of breast carcinoma cells. Breast Cancer 2000;7:221-30.
26. Prest SJ, Rees RC, Murdoch C, et al. Chemokines induce the cellular migration of MCF-7 human breast carcinoma cells: subpopulations of tumour cells display positive and negative chemotaxis and differential in vivo growth potentials. Clin Exp Metastasis 1999;17:389-96.
27. Murphy LC, Dotzlaw H, Wong MS, et al. Epidermal growth factor: receptor and ligand expression in human breast cancer. Semin Cancer Biol 1990;1:305-15.
28. Murphy LJ, Sutherland RL, Stead B, Murphy LC, Lazarus L. Progestin regulation of epidermal growth factor receptor in human mammary carcinoma cells. Cancer Res 1986;46:728-34.
29. Higashiyama M, Doi O, Kodama K, et al. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer 1997;75:1302-8.
30. Hori M, Shimazaki J, Inagawa S, Itabashi M. Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor a and lack of MDM2 mRNA splice variants in human breast cancer. Breast Cancer Res Treat 2002;71:77-83.
31. Onel K, Cordon-Cardo C. MDM2 and prognosis. Mol Cancer Res 2004;2:1-8.
32. Polsky D, Melzer K, Hazan C, et al. HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst 2002;94:1803-6.